Next-generation oral SERD therapy lowers the risk of breast cancer recurrence

[News]

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy for early-stage (1-3) hormone receptor (HR)-positive, HER2-negative breast cancer, significantly lowered the risk of the disease returning when compared with standard hormone therapies long considered the backbone of treatment.

More... (https://www.news-medical.net/news/20251210/Next-generation-oral-SERD-therapy-lowers-the-risk-of-breast-cancer-recurrence.aspx)